RE 1492C

Drug Profile

RE 1492C

Latest Information Update: 30 Aug 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma; Freie Universitat Berlin
  • Class Antiplatelets
  • Mechanism of Action Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary thrombosis; Thrombosis

Most Recent Events

  • 15 Jun 2004 Discontinued - Preclinical for Coronary thrombosis in Germany (unspecified route)
  • 15 Jun 2004 Discontinued - Preclinical for Thrombosis in Germany (unspecified route)
  • 09 Oct 2001 No-Development-Reported for Coronary thrombosis in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top